Streptococcus pyogenes colonization in children aged 24-59 months in The Gambia: Impact of Live Attenuated Influenza Vaccine and associated serological responses

Alexander J. Keeley[1,2,3], Danielle Groves[2], Edwin P. Armitage[1,3], Elina Senghore[3], Ya Jankey Jagne[3], Hadijatou J. Sallah[3], Sainabou Drammeh[3], Adri Angyal[2], Hailey Hornsby[2], Gabrielle de Crombrugghe[4,5], Pierre Smeesters[4,5], Omar Rossi[6], Martina Carducci[6], Chikondi Peno[7], Debby Bogaert[7], Beate Kampmann[1,3], Michael Marks[1,8,9], Helen A. Shaw[10], Claire E. Turner[11] and Thushan I. de Silva[1,2,3] on behalf of MRCG Strep A Study Group^.

1. Faculty of Infectious and Tropical Diseases, The London School of Hygiene & Tropical Medicine, Keppel Street, London, United Kingdom
2. Department of Infection, Immunity and Cardiovascular Disease, Medical School, The University of Sheffield, Sheffield, United Kingdom
3. Vaccines and Immunity Theme, MRC Unit The Gambia at LSHTM, PO Box 273, Banjul, The Gambia
4. Molecular Bacteriology Laboratory, Université Libre de Bruxelles, Brussels, Belgium.
5. Department of Pediatrics, Hôpital Universitaire des Enfants Reine Fabiola, Université Libre de Bruxelles, 1050 Brussels, Belgium.
6. GSK Vaccines Institute for Global Health (GVGH), Via Fiorentina 1, 53100 Siena, Italy
7. Centre for Inflammation Research, Queen's Medical Research Institute, University of Edinburgh, Edinburgh, UK
8. Hospital for Tropical Diseases, University College London Hospital, London, UK

9. Division of Infection & Immunity, University College London, London, UK

10. Vaccines Division, Scientific Research & Innovation Group, MHRA, Potters Bar, UK

11. School of Biosciences, The University of Sheffield, Sheffield, United Kingdom

^A full list of MRC Unit The Gambia StrepA Study Group members is listed in acknowledgements.

Abstract

Background

Immunity to *Streptococcus pyogenes* in high burden settings is poorly understood. We explored *S. pyogenes* nasopharyngeal colonization after intranasal live attenuated influenza vaccine (LAIV) among Gambian children aged 24-59 months, and resulting serological response to 7 antigens.

Methods

A post-hoc analysis was performed in 320 children randomized to receive LAIV at baseline (LAIV group) or not (control). *S. pyogenes* colonization was determined by quantitative Polymerase Chain Reaction (qPCR) on nasopharyngeal swabs from baseline (D0), day 7 (D7) and day 21 (D21). Anti-streptococcal IgG was quantified, including a subset with paired serum pre/post *S. pyogenes* acquisition.

Results

The point prevalence of *S. pyogenes* colonization ranged from 7-13%. In children negative at D0, *S. pyogenes* was detected at D7 or D21 in 18% of LAIV group and 11% of control group participants (p=0.12). The odds ratio (OR) for colonization over time was significantly increased in the LAIV group (D21 vs D0 OR 3.18, p=0.003) but not in the control group (OR 0.86, p=0.79). The highest IgG increases following asymptomatic colonization were seen for M1 and SpyCEP proteins.

Conclusions

Asymptomatic *S. pyogenes* colonization appears modestly increased by LAIV, and may be immunologically significant. LAIV could be used to study influenza-*S. pyogenes* interactions.

Word count:

Main text: 3478 (excluding 446 for figure legends)

Abstract: 200

Keywords:

Streptococcus pyogenes

Colonization

Carriage

The Gambia

Live Attenuated Influenza Vaccine

Serological responses

Antibodies

74 **Introduction**

75 *Streptococcus pyogenes* (Group A Streptococcus, Strep A) is responsible for half a million
76 deaths worldwide each year, through severe invasive infections and immune complications
77 including rheumatic heart disease (RHD)[1]. The greatest disease burden is experienced in low-
78 and middle-income countries (LMIC)[1, 2]. Consequently, the World Health Assembly
79 declared in 2018 that a vaccine against *S. pyogenes* is a major global health research priority.
80 An ideal vaccine would substantially reduce *S. pyogenes* transmission, disease, and perhaps
81 colonization, without provoking immune mediated complications [3]. Observational data show
82 a decrease in the incidence of *S. pyogenes* disease with increasing age, possibly due to natural
83 immunity acquired from repeated exposure [4]. Asymptomatic pharyngeal colonization with
84 *S. pyogenes* is recognized, with an estimated point prevalence of 6.6-9.7% in children [4].
85 Characterizing protective immunity generated by infections and colonization remains a major
86 knowledge gap in designing effective and safe vaccines, particularly from LMIC settings [5-
87 7].

88 Epidemiological observations have shown an association between invasive *S. pyogenes*
89 infections and respiratory viral infections, especially influenza [8]. *S. pyogenes* was
90 demonstrated to be responsible for substantial mortality in influenza pandemics of 1918 and
91 2009 [8, 9]. It is important to understand whether respiratory viruses increase colonization with
92 pathogenic bacteria such as *S. pyogenes* in the nasopharynx, as colonization may be a necessary
93 preceding event to pharyngitis and invasive disease. We have recently demonstrated that
94 intranasal live attenuated influenza vaccine (LAIV), used as a surrogate viral challenge agent,
95 induces modest increases in nasopharyngeal *Streptococcus pneumoniae* colonization and
96 density in the 21 days following vaccination in Gambian children [10]. In the current study,
97 we conducted a post-hoc analysis of this randomized controlled trial of LAIV in children aged
98 24-59 months to explore whether LAIV also induced an increase in nasopharyngeal *S.*

99 *pyogenes* colonization, and whether colonization was associated with a serological response to
100 several *S. pyogenes* antigens.
101
102 **Methods**
103 Study population and design: We carried out a post-hoc observational study nested within a
104 randomized controlled trial of LAIV, studying immunogenicity, viral shedding and
105 microbiome interactions in children aged 24-59 months in The Gambia. Children were
106 randomized 2:1 to receive LAIV at study entry (day 0, D0, LAIV group) or on day 21 (D21,
107 control group), which was the end of active follow up. The study (NCT02972957) was
108 conducted across two years in Sukuta, an urban region in The Gambia, Africa during February
109 to April 2017, and January to March 2018 [10, 11]. Children were recruited to the parent study
110 following community sensitization. All participants were influenza-vaccine naïve and
111 clinically well, with no history of respiratory illness in the prior 14 days. Participants in LAIV
112 and control groups were recruited simultaneously to avoid bias via seasonal variation. Children
113 were immunized with the Northern Hemisphere Russian-backbone Trivalent LAIV (Nasovac-
114 S, Serum Institute of India, Pune, India)[11]. Data on symptoms experienced between D0 and
115 D7 were collected at the D7 visit, and symptoms experienced between D7 and D21 recorded
116 at the D21 visit. Informed consent was sought from parents of all participants, including for
117 subsequent research on their samples. The study was approved by the Joint Medical Research
118 Council/Gambia Government ethics committee (ref: 16193).
119
120 Determination of *S. pyogenes* colonization status: Participants had a nasopharyngeal swab
121 taken at D0 (immediately prior to LAIV receipt), at D7 and D21, using flocked swabs
122 (FLOQSwabs; Copan, USA) stored in RNAprotect (Qiagen, UK). Samples were processed
123 within 4 h of collection and stored at −70°C until further processing. DNA was extracted from

124 200µl of RNAprotect using the AGOWA Mag Mini DNA extraction kit (LGC Genomics,
125 Berlin, Germany) in combination with phenol-bead beating as previously described[12].
126 Standard curves were generated via extraction of total genomic DNA from the *S. pyogenes*
127 H293 reference strain, ranging from 1 to 10,000,000 genome copies per µL. Quantitative PCR
128 was performed using QuantStudio™ 5 Real-Time PCR System, using primers and probes to
129 detect the *S. pyogenes* specific gene *speB* (Forward: CTAAACCCTTCAGCTCTTGGTACTG,
130 Reverse: TTGATGCCTACAACAGCACTTTG, Probe: Cy5-
131 CGGCGCAGGCGGCTTCAAC-BHQ2) [13]. A cycle threshold of 40 was defined as positive,
132 but all curves above CT threshold of 35 were checked manually to ensure appearance was
133 consistent with true amplification of the target. Samples were run in triplicate. Where only one
134 of the triplicates showed the presence of *S. pyogenes*, samples were repeated and only defined
135 as positive if at least two triplicates were positive on repeat testing. A participant with positive
136 qPCR result at a given timepoint was considered colonized. All participants were included in
137 the colonization study group. Participants who were negative at baseline were included in the
138 acquisition study group (figure 1).
139
140 Antibody measurement: Blood was collected in serum separation tubes from participants in the
141 LAIV group, for study endpoints on influenza vaccine immunogenicity [11]. For the serology
142 study participants were categorised as colonized if *S. pyogenes* was detected by qPCR at any
143 time point. Participants in the acquisition study group (negative at day 0) were categorised as
144 newly-colonized if *S. pyogenes* was detected at either D7 or D21. All available serum collected
145 on D21 from colonized participants was tested, along with a random selection from non-
146 colonized participants (a 1:1.5 ratio of colonized to non-colonized participants). Of newly-
147 colonized participants, a subgroup of 18 had paired serum (pre/post colonization) available for
148 testing.

149

150 Enzyme-linked immunosorbent assay (ELISA) optimization was performed to determine
151 optimal *S. pyogenes* protein coating concentrations, blocking buffer solution, serum dilution
152 and secondary antibody concentration. 96-well flat-bottomed high binding ELISA plates were
153 coated overnight with several recombinant proteins in pH 9.6 carbonate buffer: *S. pyogenes*
154 cell envelope protease (SpyCEP) at 0.16µg/ml, *S. pyogenes* Adhesion and Division protein
155 (SpyAD) at 1µg/ml, M1 protein at 0.5µg/ml, Mac/IdeS protein (henceforth referred to as Mac)
156 at 1 µg/ml, and Collagen binding protein (Cpa) at 0.16 µg/ml. Proteins were provided by
157 National Institute for Biological Standards and Control, MHRA, UK (Supplementary
158 data)[14]. Blocking and serum dilution was performed using 1% casein blocking buffer
159 (ThermoFisher Scientific, USA). Serum was diluted to 1:100 for Cpa and Mac, and 1:800 for
160 M1, SpyCEP and SpyAD, and applied to protein coated wells. Bound IgG was detected with
161 goat anti-human IgG-HRP conjugate (Invitrogen, USA), diluted to 1:500, then incubated with
162 SureBlue TMB 1-Component Peroxidase Substrate (KPL). The reaction was stopped with 1%
163 hydrochloric acid and optical density (OD) was read at 450nm, subtracting background OD.
164 Six washes were performed between each ELISA step with 0.05% Tween-20 in phosphate
165 buffered saline (PBS). In order to quantify anti-protein IgG activity in participant sera, 12 serial
166 three-fold dilutions of pooled human immunoglobulin (Gammanorm, Octapharm) were used
167 to generate standard curves commencing at 1:33.3 dilution (14.85mg/mL) in 1% casein buffer.
168 Seroconversion between D0 and D21 was considered as a 2-fold rise in antibody titre, or 4-
169 fold rise in antibody titre if raw optical density measurements were <0.25 at baseline, as per
170 previously published definitions [15]

171

172 In order to measure antibody titres to the additional vaccine antigens Group A carbohydrate
173 (GAC) and Streptolysin O (SLO), an optimized 4-plex (GAC, SLO, SpyCEP, SpyAD) serology

174 assay using the Luminex platform was performed on all available sera using protocol described
175 [16]. All antigens were supplied by GSK Vaccine Institute for Global Health (GVGH). All sera
176 with ELISA data were tested, except two samples from non-colonized participants, where there
177 was no remaining volume. Samples were tested in duplicate at a dilution of 1:8100 alongside
178 standard curves derived from pooled intravenous immunoglobulin (Privigen, CSL Behring).
179 Mean florescence intensity was measured for each antigen with a Luminex 200 instrument
180 (Invitrogen).
181
182 Statistical analysis: All statistical analysis was performed in R (version 4.0.1). Comparison of
183 *S. pyogenes* colonization status and incident acquisition between children who received LAIV
184 and those who did not was performed using chi-squared test. In addition, logistic and
185 generalized mixed effects logistic regression models, accounting for multiple timepoint
186 sampling from individuals, were used to explore the change in colonization status over time
187 within the vaccinated and unvaccinated groups, as previously described [10]. Co-variates
188 included were age in months, sex, the presence of asymptomatic respiratory viruses at baseline,
189 timepoint (D0 vs D7, D0 vs D21) and receipt of LAIV [10, 11].
190
191 Samples where optical density measured by ELISA fell below the detection limit of the
192 standard curve, were allocated a random value between zero and the limit of detection.
193 Antibody titres in Luminex data were interpolated using xPonent 4.2 software (Luminex
194 Corporation) using 5-parameter logistic regression. For the 4-plex Luminex assay, where both
195 limit of accurate quantification and detection were characterized, results falling below
196 respective limits were randomly assigned a value between zero and the lowest value of each
197 limit [16]. Antibody data (IVIG–adjusted anti-protein activity in mg/mL for ELISA and
198 Relative Luminex Units (RLU/mL) for Luminex assay) were Log transformed and assessed for

199 normality using QQplot and the shapiro-wilk test. Log transformed antibody quantities
200 between groups were compared using Student's t-test. Paired Student's t-test was performed to
201 compare antibody levels before and after *S. pyogenes* colonization from individual participants.
202 A p value of <0.05 was considered statistically significant.
203
204 **Results**
205 *S. pyogenes* colonization prevalence and incidence: A total of 320 participants were included
206 in this study, of which 212 received LAIV (Figure 1). Overall, 71/320 (22%) children were
207 colonized with *S. pyogenes* on at least one time point within the 21-day study period. At D0
208 26/320 (8%) participants were colonized, 13 in the LAIV (6%) and 13 in control (12%) groups
209 (p=0.068, Table S1). In the acquisition study group, 45 (15%) had acquired colonization by
210 D7 or D21 (Table 1), 35/199 (18%) in LAIV group and 10/95 (11%) in control group (Table
211 1, p=0.12). A logistic regression model was used to explore the odds of new *S. pyogenes*
212 colonization at either D7 or D21 in the acquisition study group (n=294), accounting for age,
213 sex, LAIV receipt and the presence of other respiratory viruses at D0 (Table S2), showing no
214 significant association between LAIV and *S. pyogenes* acquisition (OR 1.92, 0.93-4.31,
215 p=0.09).
216



Figure 1. Study profile. *320 participants randomized 2:1 to the LAIV (day 0 vaccine) or control (day 21 vaccine) group. All participants (colonization study group) had S. pyogenes colonization status determined by real-time PCR at day 0, 7 and 21. 294 participants (the acquisition study group) were negative at baseline. Only participants receiving LAIV at day 0 had serum taken at days 0 and 21 (n=212). Serum from day 21 was available from 40/48 participants from LAIV group who were colonized at any time point and from 61/164 randomly selected non-colonized participants. Paired serum (pre/post colonization) was available from 18/35 participants who acquired colonization during the study period. LAIV = Live attenuated Influenza Vaccine.*

228

229 ***Table 1. Streptococcus pyogenes acquisition during the 21-day study period***. *Included below*

230 *are n=294 in the acquisition study group.*

Time point	*N*	*Overall, N = 294*[1]	*Control, N = 95*[1]	*LAIV, N = 199*[1]	*p-value*[2]
Day 7	294	18 (6%)	3 (3%)	15 (8%)	0.14
Day 21	294	35 (12%)	8 (8%)	27 (14%)	0.2
Any time	294	45 (15%)	10 (11%)	35 (18%)	0.12

231 [1]n(%)

232 [2]Pearson's Chi-squared test

233

234 In order to explore changes in colonization status within an individual over time in all children

235 (n=320), a generalized logistic mixed effects regression model was used to explore the odds of

236 *S. pyogenes* colonization over time, accounting for age, sex, LAIV receipt and the presence of

237 other respiratory viruses at D0 (Table S3). As an interaction was observed between LAIV

238 receipt and the D21 timepoint terms in this model, we constructed separate models for the

239 LAIV and control groups. The odds ratio (OR) of *S. pyogenes* colonization was higher at D21

240 compared to day D0 in the LAIV group (OR 3.18, 95% CI 1.49-6.81, p=0.003, Table 2) but

241 not day 7 (OR 1.30, 95% CI 0.57-2.97, p=0.54). The OR of *S. pyogenes* colonization in the

242 control group was not higher at either D7 (OR 0.34, 95% CI 0.09-1.27, p=0.11) or D21 (OR

243 0.86, 95% CI 0.3-2.51, p=0.79) when compared to D0 (Table S4).

244

245 Only 17 of 71 (23.9%) participants with *S. pyogenes* detected during the study were colonized

246 at two timepoints, with only 2 (2.8%) colonized at all three study time points (Figure S1). No

247 difference in qPCR quantified *S. pyogenes* density was observed between LAIV and control

248 participants at any timepoint nor over time (Table S5).

249

250 ***Table 2. Factors associated with S. pyogenes colonization in the live attenuated influenza***

251 ***vaccine (LAIV) group.***

	OR	*95% CI*	*p-value*
Day 7 (vs day 0)	1.30	0.57-2.97	0.540
Day 21 (vs day 0)	3.18	1.49-6.81	**0.003**
Positive respiratory virus at day 0	1.54	0.72-3.29	0.266
Age in months	0.97	0.93-1.01	0.162
Sex Male (vs female)	0.97	0.47-2.04	0.945

252

253 *p-values for factors associated with Streptococcus pyogenes colonization are derived from a*

254 *generalized logistic mixed effects model, taking into account changes within individuals over*

255 *time. OR = odds ratio, CI = confidence interval.*

256

257 We compared symptom data during the study period for all 294 children in the acquisition

258 study group. Ten children had infected skin sores during the 21-day follow up, 9 in the LAIV

259 group and 1 in the control group (5% vs 1%, p=0.2, Table S6). Only three episodes of sore

260 throat were reported, all in the LAIV group (Table S6). Skin sores were more common in those

261 who became colonized (9% vs 2% p=0.05) (Table S6). No statistically significant difference

262 in fever, cough, rhinorrhoea, or sore throat was seen in children who acquired *S. pyogenes*

263 compared to those who did not (Table S6). In the total study group only 6/71 (9%) colonized

264 participants had either a sore throat or an infected skin sore.

265

266 Serological responses to *S. pyogenes* antigens: ELISA-quantified serum antibody titres at D21
267 in 40 colonized participants were compared with those in 61 randomly selected non-colonized
268 participants (all from the LAIV group due to sera availability). The age was not significantly
269 different between participants included in serological study who were colonized compared to
270 non-colonized controls (median age in months 36 vs 32, p=0.3, Table S6). Sera from colonized
271 participants demonstrated significantly higher IVIG-adjusted IgG levels to M1, SpyCEP,
272 SpyAD and Mac, but not Cpa, compared to non-colonized participants (Figure 2A). Paired
273 serum was available for 18/35 newly-colonized participants. Mean M1- and SpyCEP-specific
274 IgG titres were significantly increased at D21 compared to D0, but not IgG titers to SpyAD,
275 Mac or Cpa (Figure 2B). The proportion of newly-colonized participants who seroconverted
276 pre/post colonization was greatest for M1 and SpyCEP (Figure 2C). To explore serological
277 responses further, a recently described 4-plex assay was used to quantify antibodies to
278 additional *S. pyogenes* vaccine antigens GAC and SLO, along with SpyCEP and SpyAD. This
279 assay was tested on 99/101 samples with ELISA-quantified anti-*S. pyogenes* titres [16]. Sera
280 from colonized children demonstrated significantly higher titres to GAC, SLO and SpyCEP
281 but not to SpyAD (Figure 3A). In the subset of participants with *S. pyogenes* acquisition during
282 the 21-day study period (n=18), differences in IgG titers at D0 and D21 were not statistically
283 significant (Figure 3B). Antibody titres to SpyCEP and SpyAD that were measured by both
284 techniques were well correlated (Figure S2). Removing the participants with sore throat or
285 infected skin sores and colonization during the study had no significant impact on the
286 serological results, nor did excluding participants colonized on D21 only, nor applying a more
287 conservative definition of seroconversion (4-fold increase in IgG titre regardless of baseline
288 optical density) (Figures S3, S4, S5).
289



Figure 2. Serological responses to S. pyogenes colonization measured by ELISA. A. *Comparison of anti-protein IgG activity to Cpa, M1, Mac, SpyCEP, and SpyAD in participants (n=101) according to anytime S. pyogenes colonization status.* ***B****. Paired comparison of anti-protein IgG activity to Cpa, M1, Mac, SpyCEP, and SpyAD between day 0 and day 21 in newly colonized participants (n=18). Log_{10} transformed IVIG-adjusted anti-protein activity was compared with t-tests (unpaired and paired respectively), horizontal line depicts the median value.* ***C****. Percentage of study participants (n=18) acquiring S. pyogenes during the study who seroconverted between day 0 and day 21.*



Figure 3. Serological responses to S. pyogenes colonization measured by Luminex 4-plex. ***A.*** *Comparison of IgG activity to GAC, SLO, SpyCEP, and SpyAD in participants (n=99) according to anytime S. pyogenes colonization status.* ***B****. Paired comparison of IgG activity to GAC, SLO, SpyCEP, and SpyAD between D0 and D21 in newly-colonized participants (n=18). Log_{10} transformed IVIG-adjusted anti-antigen activity was compared with t-tests (unpaired and paired respectively). Horizontal bar depicts the median value.*

Discussion

In this post-hoc study of a randomized controlled trial set in The Gambia, we report to our knowledge the first analysis examining the impact of LAIV on *S. pyogenes* nasopharyngeal colonization in children. Using PCR to define colonization events, we observed a prevalence of 8% at the start of the study in children aged 24-59 months. Our data demonstrate only a modest impact of LAIV on *S. pyogenes* colonization rates. We observed non-significantly increased rates and odds of new colonization in the LAIV group and increased odds of

318 colonization at D21 compared to baseline in the LAIV group only. During the short 21-day
319 study duration, 22% of children were colonized at one or more timepoints, with most children
320 (73%) only colonized at one timepoint. The dynamic picture of colonization we observed may
321 be partially influenced by LAIV administration. It may also reflect how commonly children
322 are exposed to *S. pyogene*s in areas with a high burden of *S. pyogenes* disease and our findings
323 are broadly in keeping with published estimates from LMICs [4, 17].
324
325 *S. pyogenes* was demonstrated to be responsible for substantial mortality in influenza
326 pandemics of 1918 and 2009 [8, 9]. While both epidemiological and mechanistic observations
327 demonstrate that respiratory viruses, including influenza, are associated with severe *S.*
328 *pyogenes* disease, their role in modulating the host-pathogen interaction is complex and poorly
329 understood, particularly in relation to colonization of the pharynx [8, 9, 18-21]. As respiratory
330 viruses frequently infect the colonizing sites of bacteria, it is important to understand their
331 impact on potentially pathogenic bacteria such as *S. pyogenes*. While mice administered a non-
332 lethal challenge with *S. pyogenes* following an influenza challenge frequently had a severe and
333 fatal disease course [21], mice vaccinated with LAIV were protected from *S. pyogenes*
334 superinfection [20], but few models have specifically investigated the impact of respiratory
335 viruses on pharyngeal colonization [22]. With the recent establishment of a *S. pyogenes* human
336 challenge model, co-challenge studies with LAIV and *S. pyogenes* could reveal mechanistic
337 insights into the interaction between influenza virus, *S. pyogenes*, and host immune responses
338 [23]. A co-challenge study with *S. pneumoniae* and LAIV has shown how virus-induced
339 inflammatory responses and impaired innate immune responses promote bacterial colonization
340 [24]. The data provide further evidence that the impact of LAIV on colonization with
341 potentially pathogenic bacteria is only modest and supports the wider rollout of LAIV to reduce
342 influenza disease and its complications in LMICs.

343

344 We also demonstrate that asymptomatic *S. pyogenes* colonization leads to seroconversion to
345 several antigens representative of different stages in *S. pyogenes* infection, with differences in
346 antibody magnitude across the different targets measured[14]. Higher serological responses to
347 *S. pyogenes* antigens were observed in children colonized at any timepoint in our study
348 compared to non-colonized controls. Given that prior exposure to *S. pyogenes* in all children
349 in this cohort may be similar, these differences likely reflect recent exposure. The most notable
350 responses were seen to full length streptococcal M1 protein and to the envelope protease
351 SpyCEP when measured by ELISA, including a rise in titres in paired sera taken from before
352 and after colonization. Reactivity to full length M1 protein likely reflects activity to conserved
353 M protein region rather than type-specific reactivity, given that *emm*1 isolates have not been
354 identified in The Gambia[25, 26]. IgG antibodies to other antigens, SpyAD, Mac, GAC and
355 SLO, were higher in children where *S. pyogenes* colonization had been detected, but not Cpa.
356 Noting that the antigens tested via ELISA and Luminex were obtained from different sources,
357 there was broad concurrence between the two serological assays, except that IgG to SpyAD
358 was significantly higher in colonized compared to non-colonized participants when measured
359 by ELISA and not by Luminex. Nonetheless, our findings suggest that asymptomatic
360 pharyngeal colonization with *S. pyogenes* may indeed elicit an IgG immunological response to
361 multiple antigens.

362

363 Whilst "true" *S. pyogenes* colonization has been defined as colonization *without* a serological
364 response, the definition risks simplification of a complex and dynamic state influenced by host-
365 immunity, bacterial characteristics, and environmental factors. This serologically inactive
366 phenotype has been described with minimal serum antibody response to SLO and anti-DNAase
367 B (7, 32). Our data shows that serological responses are variable following asymptomatic

368 colonization to different proteins. Furthermore, in practice colonization is often defined as an
369 asymptomatic person with detectable *S. pyogenes* without serial serological testing. In detailed
370 longitudinal analyses, seroconversion has been documented following asymptomatic
371 acquisition of *S. pyogenes* in the USA and Egypt, with highest proportion of seroconversions
372 to type-specific M peptides and SpyAD [15, 27]. In another cohort study in the USA,
373 seroconversion to type-specific M protein frequently occurred following asymptomatic
374 acquisition and conferred protection from homologous strain reinfection [28].
375
376 Protection following asymptomatic colonization and historical *S. pyogenes* intranasal
377 vaccination has been observed, but the responsible mechanisms and serological corelates of
378 protection have not been identified [29-34]. Early prospective observation demonstrated the
379 emergence of acute rheumatic fever following asymptomatic *S. pyogenes* infection [35].
380 Furthermore, emerging data show that patients with rheumatic fever have serological activity
381 to significantly more *S. pyogenes* M peptides and conserved antigens compared to matched
382 controls, including activity following asymptomatic pharyngeal colonization [36, 37]. It is
383 therefore possible that asymptomatic colonization could play a role in the pathological
384 immunity that leads to acute rheumatic fever in endemic settings and warrants further
385 exploration.
386
387 Our study has several key limitations. Firstly, it was a post-hoc analysis of a study principally
388 powered for assessing the impact of LAIV on *S. pneumoniae* colonization density, and
389 interactions between the host microbiome and LAIV-specific immunity. The study was not
390 powered to detect any impact of LAIV on *S. pyogenes* density. LAIV is used as a proxy for
391 natural influenza infection and may not reflect the true dynamics of *S. pyogenes* colonization
392 during natural influenza infection. We defined colonization events by PCR and not

393 microbiological culture of *S. pyogenes*, which is considered the gold standard for defining the
394 presence of *S. pyogenes*. We have previously demonstrated that the point prevalence of
395 pyoderma in children under 5 from the same community is high at 17.4%, with *S. pyogenes*
396 cultured from 51% of pyoderma lesions [38]. We did not perform microbiological culture on
397 infected skin lesions or from sore throats in this study to be able to definitively categorize these
398 episodes as symptomatic S. pyogenes events. Nonetheless the exclusion of all participants with
399 either a sore throat or skin sore did not dramatically alter the serological findings. Due to the
400 availability of serum samples, we only measured *S. pyogenes*-specific antibodies in in the
401 LAIV group, so no comparison between vaccinated and unvaccinated groups was possible.
402 Finally, PCR to a single preserved and specific *S. pyogenes* target does not allow for assessment
403 of *emm*-type specific immunity, which is an historically important consideration for *S.*
404 *pyogenes* serological activity.
405
406 Nonetheless, our study does provide several important findings. Understanding both naturally
407 occurring protective immunity and pathological autoimmunity to *S. pyogenes* from settings
408 with the highest disease burden is of paramount importance to progress towards a safe and
409 effective *S. pyogenes* vaccine. Our study adds further evidence that asymptomatic colonization
410 may be immunologically significant, particularly in the context of influenza co-infection.
411 Further research combining longitudinal observation, with detailed microbiological and
412 immunological investigation should be prioritised from areas of high disease prevalence to gain
413 a deeper understanding of immunity to this major human pathogen.
414
415 Acknowledgements
416 The authors would like to acknowledge and thank the Strep A Study Group at Medical
417 Research Council (MRC) Unit The Gambia at London School of Hygiene & Tropical Medicine

418 (LSHTM), Sona Jabang, Annette Erhart, Saffiatou Darboe, Abdul Karim Sesay, Peggy-Estelle
419 Tiencheu, Saikou Y. Bah, Lamin Jaiteh, Karen Forrest, Anna Roca, Fatoumata Camara; Peggy-
420 Estelle Tiencheu , Aru-Kumba Baldeh, Grant Mackenzie, Martin Antonio; GSK Vaccine
421 Institute of Global Health, particularly Danilo Moriel and Luisa Masai for the technical support
422 and provision of SpyCEP, Slo, GAC and SpyAD antigens for measuring IgG in Luminex 4-
423 plex assay; the dedicated team of field and nursing staff, especially Sulayman Bah and Janko
424 Camara, who delivered the study at MRC Unit The Gambia at LSHTM; Isatou Ndow for
425 clinical trial organization; the research support and clinical trials support offices at the Unit the
426 Serum Institute of India for donating the vaccines for the study. Most importantly we thank the
427 study participants and their parents who took part in the study.
428

429 References:

430 1. Carapetis JR, Steer AC, Mulholland EK, Weber M. The global burden of group A
431 streptococcal diseases. Lancet Infect Dis **2005**; 5:685-94.
432 2. Watkins DA, Johnson CO, Colquhoun SM, et al. Global, Regional, and National Burden of
433 Rheumatic Heart Disease, 1990-2015. N Engl J Med **2017**; 377:713-22.
434 3. World Health O. WHO preferred product characteristics for group A streptococcus
435 vaccines. Geneva: World Health Organization, **2018**.
436 4. Oliver J, Malliya Wadu E, Pierse N, Moreland NJ, Williamson DA, Baker MG. Group A
437 Streptococcus pharyngitis and pharyngeal carriage: A meta-analysis. PLoS Negl Trop Dis
438 **2018**; 12:e0006335.
439 5. Vekemans J, Gouvea-Reis F, Kim JH, et al. The Path to Group A Streptococcus Vaccines:
440 World Health Organization Research and Development Technology Roadmap and Preferred
441 Product Characteristics. Clinical Infectious Diseases **2019**; 69:877-83.

442 6. Martin J. The Streptococcus pyogenes Carrier State. In: Ferretti JJ, Stevens DL, Fischetti
443 VA, eds. Streptococcus pyogenes : Basic Biology to Clinical Manifestations. Oklahoma City
444 (OK), **2016**.
445 7. Kaplan EL. The group A streptococcal upper respiratory tract carrier state: an enigma. J
446 Pediatr **1980**; 97:337-45.
447 8. Louie J, Jean C, Chen TH, et al. Bacterial Coinfections in Lung Tissue Specimens from Fatal
448 Cases of 2009 Pandemic Influenza A (H1N1) - United States, May-August 2009. Atlanta,
449 United States: U.S. Center for Disease Control, **2009**:1071-4.
450 9. Morens DM, Fauci AS. The 1918 Influenza Pandemic: Insights for the 21st Century. The
451 Journal of Infectious Diseases **2007**; 195:1018-28.
452 10. Peno C, Armitage EP, Clerc M, et al. The effect of live attenuated influenza vaccine on
453 pneumococcal colonisation densities among children aged 24-59 months in The Gambia: a
454 phase 4, open label, randomised, controlled trial. Lancet Microbe **2021**; 2:e656-e65.
455 11. Lindsey BB, Jagne YJ, Armitage EP, et al. Effect of a Russian-backbone live-attenuated
456 influenza vaccine with an updated pandemic H1N1 strain on shedding and immunogenicity
457 among children in The Gambia: an open-label, observational, phase 4 study. The Lancet
458 Respiratory medicine **2019**; 7:665-76.
459 12. Biesbroek G, Sanders EAM, Roeselers G, et al. Deep Sequencing Analyses of Low Density
460 Microbial Communities: Working at the Boundary of Accurate Microbiota Detection. PLOS
461 ONE **2012**; 7:e32942.
462 13. Dunne EM, Marshall JL, Baker CA, et al. Detection of group a streptococcal pharyngitis by
463 quantitative PCR. BMC Infectious Diseases **2013**; 13:312.
464 14. Shaw HA, Ozanne J, Burns K, Mawas F. Multicomponent Vaccines against Group A
465 Streptococcus Can Effectively Target Broad Disease Presentations. Vaccines. Vol. 9, **2021**.

466 15. Hysmith ND, Kaplan EL, Cleary PP, Johnson DR, Penfound TA, Dale JB. Prospective
467 Longitudinal Analysis of Immune Responses in Pediatric Subjects After Pharyngeal
468 Acquisition of Group A Streptococci. Journal of the Pediatric Infectious Diseases Society
469 **2017**; 6:187-96.
470 16. Keeley AJ, Carducci M, Massai L, et al. Development and Characterisation of a Four-Plex
471 Assay to Measure Streptococcus pyogenes Antigen-Specific IgG in Human Sera. Methods
472 Protoc **2022**; 5.
473 17. DeWyer A, Scheel A, Webel AR, et al. Prevalence of group A β-hemolytic streptococcal
474 throat carriage and prospective pilot surveillance of streptococcal sore throat in Ugandan
475 school children. Int J Infect Dis **2020**; 93:245-51.
476 18. de Gier B, Vlaminckx BJM, Woudt SHS, van Sorge NM, van Asten L. Associations between
477 common respiratory viruses and invasive group A streptococcal infection: A time-series
478 analysis. Influenza and Other Respiratory Viruses **2019**; 13:453-8.
479 19. Okahashi N, Sumitomo T, Nakata M, Kawabata S. Secondary streptococcal infection
480 following influenza. Microbiology and Immunology **2022**; 66:253-63.
481 20. Okamoto S, Kawabata S, Fujitaka H, Uehira T, Okuno Y, Hamada S. Vaccination with
482 formalin-inactivated influenza vaccine protects mice against lethal influenza Streptococcus
483 pyogenes superinfection. Vaccine **2004**; 22:2887-93.
484 21. Okamoto S, Kawabata S, Nakagawa I, et al. Influenza A virus-infected hosts boost an
485 invasive type of Streptococcus pyogenes infection in mice. J Virol **2003**; 77:4104-12.
486 22. Bai X, Yang W, Luan X, et al. Induction of cyclophilin A by influenza A virus infection
487 facilitates group A Streptococcus coinfection. Cell Reports **2021**; 35:109159.

488 23. Osowicki J, Azzopardi KI, Fabri L, et al. A controlled human infection model of
489 *Streptococcus pyogenes* pharyngitis (CHIVAS-M75): an observational, dose-finding study.
490 The Lancet Microbe **2021**; 2:e291-e9.
491 24. Jochems SP, Marcon F, Carniel BF, et al. Inflammation induced by influenza virus impairs
492 human innate immune control of pneumococcus. Nature Immunology **2018**; 19:1299-308.
493 25. Bah SY, Keeley AJ, Armitage EP, et al. Comparative genomic analysis of skin and soft
494 tissue Streptococcus pyogenes isolates from low- and high-income
495 settings. bioRxiv **2021**:2021.09.10.459590.
496 26. Jabang S, Erhart A, Darboe S, et al. Molecular Epidemiology of Group A Streptococcus
497 Infections in The Gambia. Vaccines **2021**; 9.
498 27. el-Kholy A, Sorour AH, Houser HB, et al. A three-year prospective study of streptococcal
499 infections in a population of rural Egyptian school children. J Med Microbiol **1973**; 6:101-10.
500 28. Dunlap MB, Harvey HS. The Carrier State and Type-Specific Immunity in Streptococcal
501 Disease. American Journal of Diseases of Children **1967**; 114:229-43.
502 29. Bloomfield AL, Felty AR. Prophylactic vaccination against acute tonsillitis. Bull Johns
503 Hopkins Hosp **1923**; 34:251-3.
504 30. Lewnard JA, Whittles LK, Rick AM, Martin JM. Naturally Acquired Protection Against
505 Upper Respiratory Symptoms Involving Group A Streptococcus in a Longitudinal Cohort
506 Study. Clin Infect Dis **2020**; 71:e244-e54.
507 31. D'Alessandri R, Plotkin G, Kluge RM, et al. Protective studies with group A streptococcal
508 M protein vaccine. III. Challenge of volunteers after systemic or intranasal immunization
509 with Type 3 or Type 12 group A Streptococcus. J Infect Dis **1978**; 138:712-8.

510 32. Polly SM, Waldman RH, High P, Wittner MK, Dorfman A. Protective studies with a group
511 A streptococcal M protein vaccine. II. Challange of volenteers after local immunization in the
512 upper respiratory tract. J Infect Dis **1975**; 131:217-24.
513 33. Tsoi SK, Smeesters PR, Frost HRC, Licciardi P, Steer AC. Correlates of Protection for M
514 Protein-Based Vaccines against Group A Streptococcus. Journal of immunology research
515 **2015**; 2015:167089-.
516 34. Cope JB, Redys JJ, Randolph MF. A Comparison of Two Streptococcal Antibody Levels in
517 Posttreatment Carriers of Group A Streptococci: The Relationship between Elevated Titers
518 and Clinical Relapse as Determined by a New Serologic Procedure. Clinical Pediatrics **1976**;
519 15:1120-2.
520 35. Gordis L, Lilienfeld A, Romeo R. An Evaluation of the Maryland Rheumatic Fever Registry.
521 Public Health Reports (1896-1970) **1969**; 84:333-9.
522 36. Lorenz N, Ho TK, McGregor R, et al. Serological profiling of group A Streptococcus
523 infections in acute rheumatic fever. Clinical Infectious Diseases **2021**; 73:2322-5.
524 37. Whitcombe AL, McGregor R, Bennett J, et al. Increased breadth of Group A
525 Streptococcus antibody responses in children with Acute Rheumatic Fever compared to
526 precursor pharyngitis and skin infections. The Journal of Infectious Diseases **2022**:jiac043.
527 38. Armitage EP, Senghore E, Darboe S, et al. High burden and seasonal variation of
528 paediatric scabies and pyoderma prevalence in The Gambia: A cross-sectional study. PLoS
529 neglected tropical diseases **2019**; 13:e0007801.
530

Footnote Page

Funding:

This research was funded by Wellcome Trust in part by an Intermediate Clinical Fellowship award to TIdS [Grant no: 110058/Z/15/Z] and in part by a Clinical PhD fellowship in Global Health award to AJK [Grant no: 225467/Z/22/Z]. For the purpose of open access, the author has applied a CC BY public copyright licence to any Author Accepted Manuscript version arising from this submission.

Conflicts of interest.

O.R. and M.C are employees of the GSK group of companies. GSK Vaccines Institute for Global Health Srl is an affiliate of GlaxoSmithKline Biologicals SA. OR reports ownership of GSK share options. We declare there are no conflicts of interest among other authors

Corresponding Author:

Alexander Keeley, Vaccines and Immunity Theme, MRC Unit The Gambia at LSHTM, PO Box 273, Banjul, The Gambia, alexander.keeley@lshtm.ac.uk

Previous presentation:

The preliminary data from this study were presented at Lancefield Symposium for Streptococcal and Streptococcal Diseases, Stockholm 2022, and at European Congress of Clinical Microbiology and Infectious Diseases 2021, Online.